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FIVE YEARS ago, I inherited from my predecessor a colony of 'junkie monkeys', 
M a c c a  mula t ta  rhesus monkeys that are kept physically dependent by gwmg them 
morphine sulfate, 3 mg/kg subcutaneously four umes each day. For the past 25 years, 
this monkey colony has been used to evaluate the physical dependence habiilty of 
drugs of the morphine family. The colony has been one part of a structure, designed 
and operated by the late Nathan B. Eddy, for the purpose of keeping off the American 
market any dangerous, new addictive drugs. The American people, fnghtened for 
many years by the spectre of the drug-crazed dope fiend, is wdhng, from Ume to Ume, 
to give pohUcal support to programs for the control of drug abuse. 
Nathan B. Eddy created such a program. It flourished dunng the 1930's but perished 
in the early 1940's during World War II. Immediately after that war, because of the 
knowledge that the Germans had invented mependme (pethldme), methadone and 
perhaps many other potent narcoUc analgesics, Eddy's program was re-established 
and expanded. A committee, now known as the Committee on Problems of Drug 
Dependence, was estabhshed as an arm of our Nauonal Academy of Sciences- 
National Research Council (NAS-NRC). For all pracUcal purposes, Eddy was the 
Committee on Problems of Drug Dependence In the name of the Committee, he 
collected money from pharmaceutical industry to support research acuvmes. Over a 
period of two decades, much of that research money went to Ann Arbor, .M|chigan, 
where Maunce H. Seevers used it to estabhsh and mmnta|n a colony of morphme- 
dependent monkeys. The primary purpose of this colony was to prevent the over- 
loading of the colony of human volunteer addicts at the Addicuon Research Center at 
Lexington, Kentucky. By screening drugs first at Michigan, It was possible to channel 
the human resources to the most interesting and important drugs. 
In order for a new drug (narcoUc or otherwise) to be admitted to the Amencan 
market, it must first be approved by our Food and Drug AdministraUon. In the case of 
a narcotic drug, the FDA would not approve a drug unless it had been tested and 
recommended by the Lexington group. Lexington would not examine a new drug 
unless it had been evaluated for its physical dependence habillty at the Michigan 
facility. This chmn of evaluations was superwsed by the Committee on Problems of 
Drug Dependence. 
In pracUce, a manufacturer wanting approval of a new narcot|c drug would submit a 
sample of it to the Committee, where Eddy (or his successors) would perform an 
analgesic evaluauon using the mouse hot-plate test. Then some of the drug would be 
sent to Seevers at Michigan. It would be ]denufied only by a code number and it 
would be accompamed by only a recommended starting dose and, occasionally, by 
suggestmns for solubillzing the material Thus, Seevers and his colleagues never knew 
the source of a tested compound, ItS chem|cal structure, ~ts metabolic fate or any 
other such mformaUon at the Ume that the drug was being tested. 
The tests now used at The University of Michigan are essenually the same as they 
were m 1957 when the first unknown compounds were evaluated in the program 
Since that Ume, approximately 1000 compounds have been studied 
The first step m the evaluaUon ts always the Single Dose Suppression (SDS) The 
monkeys normally receive morph|ne four times every day, at 1 a.m., 7 a.m., 1 p.m and 
519 
520 HENRY H SW~dN 
7 p m. However, about once a week, the animals are put into abstinence by wRholding 
two consecutive morphine doses. They receive the regular 7 p.m. dose but their I a.m 
and 7 a.m. mjectmns are omitted. By 9 a.m., the animals are 14 hr abstinent, and the 
test is ready to begin. At that point the monkeys are at a mid-point in the spectrum of 
the abstinence syndrome, which we grade on a scale created by Seevers and modified 
over time. On that scale, 0 signifies that there are no abstinence signs at all and 6 
describes an animal so ill that there begins to be a danger of losing its lde. The 14 hr 
abstinent monkey is usually between grades 3 and 4 on the Seevers scale. 
A dose of a drug to be tested is admimstrered subcutaneously at the 14th hour, and 
the severity of abstinence signs is evaluated periodically for the next 4 hr, untd it Is 
time for the next regular morphine injectaon (1 p m.). Under these conditions, If the 
test drug Is: 
(a) ineffectave--the abstinence signs will continue to develop, so that by the end of 
the four-hour observaaon per/od the animal will be between 4 and 5 on the Seevers 
scale; 
(b) morphine like--the abst/nence signs wdl become less severe and, If the dose is 
sufficient, suppressed all together. Stall larger doses cause morphine-like CNS depres- 
sion, stupor and even resp/ratory depression. The time of maximum effect vanes from 
compound to compound, but is usually between 1 and 2 hr after administration, 
(c) a narcotic antagonist--the abstinence syndrome promptly becomes more severe: 
(d) a CNS depressant not of the morphine type--the monkeys show sedative, 
hypnotic and related effects without appreciable change m the abstinence signs--a 
d~stmctlon which can be made by an expenenced observer 
Related tests are used as appropnate. Non-withdrawn animals are used when the 
test drug seems to be a narcotic antagonist (because It increases the seventy of signs 
In the SDS test). In this test, the monkeys receive then- regular morphine doses until 
2 hr before the test drug is given. Therefore, in the non-withdrawn test, the animals 
start at 0 rather than at 3 or 4 on the Seevers scale. Even quite weak antagonists 
produce visible abslanence signs in non-withdrawn, morphine-dependent monkeys. 
Normal (non-dependent) monkeys are used occasmnally for one of two purposes: 
(a) to see whether naloxone wdl reverse the depressant actions of a single, large dose 
of the test drug, and (b) to determ/ne whether the test drug (if it seems to be an 
antagonist) will antagonize the depressant actions of a single large dose of morphine 
or meperidine. 
Oral admmlstratmn is employed occasionally by passing a gastric tube in a cha/r- 
restrained monkey, and delivering the drug via the tube as either a solution or a 
suspension. 
Twenty-four-hour substitution involves the replacement of not just a single mor- 
phine dose but of a whole day's morphine by giving repeated doses of the test drug. 
This may prove useful when the Single Dose Suppression test gives equivocal results 
in which it is unclear whether the parual suppression of abstinence signs is specific 
(morphine-like) or nonspecific. If the suppression is nonspectfic, the abstinence signs 
will continue to grow more severe in sp~te of repeated administration of the test drug. 
It is possible for a drug to be a narcotic-type agonist and still not produce complete 
suppression of abstinence signs in the Single Dose Suppression, if the acute toxicity 
of the drug precludes giving a totally effective dose. Convulsions are by far the most 
common dosage-lnnmng acute toxic sign with this family of drugs. In fact, one can 
conclude that all narcotics are convulsants but there is a large range, among 
compounds, m the ratio between the abstinence-suppressmg dose and the convuisant 
dose. At one end of this range is morphine, for which the convulsant dose is so 
relatively large that in the monkey (and in man) convulsions are seen only under very 
special cn.cumstances. At the other end of this range are such well-known drugs as 
codeine and propoxyphene, for which the convulsant dose is actually less than the 
dose required to completely suppress abstinence signs. 
Specms differences to the actmns of morphine are well known, but It is not always 
appreciated that a well-developed morphine-abstinence syndrome is seen only in 
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.mammals  and most ly  m higher mammals .  For  work  of this kind, the mouse ,  guinea 
pig, rabbit  and cat are quite useless.  In the rat,  an abs tmence  syndrome  can be 
produced,  but  it is far  less well deve loped  than it is m m o n k e y s  and m man In dogs, 
there is a withdrawal  syndrome  that  Is well developed,  but  act ions on the GI  t ract  in 
that  species are so marked  that  sertous in ter ference  with nu tnuon  can occur,  and this 
p revents  the long-term admmlst raUon of  morphme.  Other  species of  m o n k e y  besides 
Macaca mulatta have  been used successful ly  for  the p r o d u c u o n  of  morphine  physical  
dependence ,  but  not  all m o n k e y  species are sa t i s fac tory  For  example ,  some years  ago 
m our  labora tory ,  we tried to use the Afr ican green monkey ,  the gnve t ,  but found  it to 
be too exci table and ddiicult to t ram Therefore ,  we have  s tayed with Macaca 
mulatta 
Upon  comple t ion  of Single Dose Suppress ion and related tests,  a repor t  of  the 
results  ~s sent to the Commit tee  on Prob lems  of Drug Dependence ,  and f rom there it 
~s fo rwarded  to the manufac tu re r  Once each year ,  the Commit tee  provides  us with 
the chemical  s t ructures  of  the drugs which we have  tested,  and this mformaUon is 
incorporated into our annual report ,  which is published each  year  in the Proceed-  
ings of  the annual scientific meet ing of the Commi t t ee  on Prob lems  of Drug 
Dependence  
Occasional ly ,  af ter  he has received our  repor t ,  a drug manufac tu re r  may  contact  us 
with quest ions about  our  results or requests  for  additional tests  The mos t  commonly  
requested additional test  is the Pr imary  Addiction Study (PAS) of which we per fo rm 
approx tmate ly  six each year.  
In a PAS,  we take m onkeys  which are not  dependent  upon any drug, and over  a 
per iod of  approx imate ly  one month we give them progress ively  larger doses  of  the 
test  drug, usually on an every-6-hr  injection schedule.  On the 14th and 16th days  of  
tes t  drug adminis trat ion,  the animals  are challenged with nalorphine and naloxone,  
respect ively ,  to see whether  precipi tated abs t inence signs can be p roduced  These  
nalorphine and naloxone challenges are repea ted  on the 28th and 30th days,  respec-  
t ively On approx imate ly  the 33rd day  of the study,  the admmls t ra t ton  of  the test  drug 
is discont inued abrupt ly ,  and the ammals  are obse rved  for  stgns of  natural  withdrawal.  
P r imary  Addiction Studies emphas ize  the impor tance ,  m the product ion  of  physical  
dependence ,  of  the duration of action of  a drug with respec t  to the admimstra t ion  
Interval  A very  short-act ing drug (e.g. fentanyl) ,  which is highly e f fecuve  m sup- 
pressing the signs of  morphine  physical  dependence ,  p roduces  practical ly no phystcal  
dependence  of  its own when it Is given eve ry  6 hr for  one month  Ltkewise ,  you  
cannot  p roduce  much  dependence  to m e p e n d m e  (pethldme) if you adminis ter  it eve ry  
6 hr, though you can show dependence  if you  reduce  the rejection interval to 3 hr 
In SDS and PAS exper iments ,  the m o n k e y  has no chmce  m the mat ter ,  he Is 
captured  and injected with a drug. H o w e v e r ,  this is not the case with our self- 
injection animals  These  m onkeys  have  been prepared  surgically with a plasUc 
ca theter  inserted into the superior  vena  cava  with its tip at the level of  the right a t r ium 
of the heart  The  ca theter  exits f rom the animal via a skin recision be tween the 
scapulae The  animal wears  a harness  which is connec ted  to the wall of  the cage by a 
hinged, hollow tube through which the ca the ter  passes  to a pump  behind the cage The 
pump dehvers  drug solution f rom a reservoir ,  through the ca theter  to the monkey  at 
appropr ia te  t imes 
The animal works  on a fixed-raUo schedule of  30 presses  of  a lever  to receive one 
in t ravenous  in jecuon of drug solution (an FR 30 schedule) Normal ly  the animal 
works  for  codeme  m a dose of  0 3 mg/kg/mjecUon for  two 1-hr sessions each day For  
codeine,  the m o n k e y  will maintain a rate of  lever-pressing be tween 2.0 and 2.5 
responses / sec  for  the hour  At every  fourth session,  e~ther saline or a test  drug is 
subst i tuted for  codeine,  and the response  rate ~s measured  For  saline, the response  
rate approaches  zero;  for  act ive,  morphme-hke  drugs, the d o s e - r e s p o n s e  relat ionship 
Is an reverted U-shaped  curve.  (That  Is to say, for  m o r p h m e  and many  other  act ive 
drugs, there is a concen t ra tmn below which the ammal  behaves  as ~f ~t were  sahne and 
will not work  for  ~t, there ~s an opt imal  concentra t ion  of drug at which the m o n k e y ' s  
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response rate may approach that seen with codeine; and above that opUmal concen- 
tration of drug, the response falls off toward zero ) 
In the self-administration test, the monkeys w~ll press a lever to receive the 
standard narcotic agents--morphine, codeine, mependme, methadone, heroin, etc. 
They will not work for the so-called kappa receptor agomsts, ketocyclazocine and 
ethylketocyclazocme. For the m~xed agomst-antagomsts, the answer ~s sometimes 
'yes' and sometimes 'no'; they will not work for naiorphine or naloxone, they w~ll give 
a few responses for proplram, and they will work energetically for buprenorphme The 
monkeys wtll work for a variety of non-narcotic drugs--barbiturates and alcohol, 
cocaine and amphetamine. They will n o t  work for chlorpromazine or for LSD. With 
d~azapam, the results are eqmvocal: Yanag~ta has been able to get the monkey to 
work for the benzodiazepine, while other workers with shghtly different experimental 
condlUons have obtmned negative results. 
At the present time, the future of this dependence evaluation program is qmte 
uncertain in the Umted States. Several factors which are involved are" 
(a) The Committee on Problems of Drug Dependence is no longer affihated with the 
Nauonai Academy of Sciences-National Research Council. On July 1, 1976 it became 
a free-standing committee 
(b) The Addiction Research Center at Lexington, Kentucky no longer uses human 
volunteers to test the drugs which have passed the Michigan screen. The use of 
prisoner addicts ended on January l, 1977 
(c) Our Food and Drug AdmmlstraUon has not decided what kind of prechmcal 
testing will be required for potent analgesics m the future, though it is safe to say that 
some form of dependence evaluatmn will be demanded for a long tlme to come. 
Thus, we seem to be at the end of an era--the era of Nathan B Eddy. A new era 
will soon begin, but we do not know what criteria will be selected and what tests will 
be reqmred by governments which are seeking to 'pro tec t  their citizens from 
enslavement by dependence-producing drugs. 
